Progressive Multifocal Leukoencephalopathy (PML)
Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease of the central nervous system caused by reactivation of JC polyomavirus (JCPyV) in immunocompromised individuals. First described in 1958 in patients with hematologic malignancies, PML gained prominence during the HIV/AIDS epidemic and has re-emerged as a critical concern with the expanding use of immunomodulatory therapies in neurology — particularly natalizumab for multiple sclerosis. The disease produces progressive, multifocal white matter destruction without a significant inflammatory response, leading to cumulative neurologic disability and frequently death. Early recognition, prompt diagnostic workup, and understanding of the distinct risk profiles associated with different immunosuppressive settings are essential for the practicing neurologist.
Bottom Line
- Pathogen: JC polyomavirus (JCPyV) reactivation in the setting of impaired cellular immunity — seroprevalence in the general population is 50–70%, but PML is exceedingly rare in immunocompetent individuals
- Risk settings: HIV/AIDS (CD4 <200, historically the most common cause), natalizumab therapy for MS, rituximab, hematologic malignancies, organ transplantation, and other immunosuppressants
- Natalizumab risk stratification: JCV antibody index >1.5, prior immunosuppressant use, and treatment duration >24 months are the three major risk factors; their combination defines a risk gradient from <1/10,000 to >1/100
- Clinical presentation: Subacute focal neurologic deficits (hemiparesis, visual field cuts, cognitive decline, ataxia) progressing over weeks — characteristically without fever, headache, or meningismus
- Imaging hallmark: Asymmetric, multifocal white matter lesions involving subcortical U-fibers, T2/FLAIR hyperintense, without mass effect or contrast enhancement; parieto-occipital predilection; restricted diffusion at the advancing edge
- Diagnosis: Compatible MRI pattern plus CSF JCV PCR (sensitivity ~75–80%, specificity ~95%); brain biopsy reserved for CSF-negative cases with high clinical suspicion
- Treatment: No direct antiviral exists; restore immune competence (ART for HIV, discontinue causative immunosuppressant); PLEX for natalizumab-PML; manage PML-IRIS with corticosteroids if severe
- Prognosis: 30–50% mortality in HIV-PML; ~25% mortality in natalizumab-PML if detected early; survivors often have significant residual disability
Virology and Pathogenesis
JC polyomavirus is a small, non-enveloped, double-stranded DNA virus of the Polyomaviridae family. Primary infection typically occurs in childhood, is clinically silent, and establishes latency in the kidneys, bone marrow, and lymphoid tissue. Viral shedding in urine is detectable in 20–30% of immunocompetent individuals.
Mechanism of PML Development
PML results from a convergence of viral and host factors. Immunosuppression — particularly impairment of CD4+ and CD8+ T-cell surveillance — permits JCPyV reactivation, genomic rearrangement of the viral non-coding control region (NCCR), and subsequent neurotropic transformation. The rearranged virus acquires the ability to infect oligodendrocytes, the myelinating cells of the CNS. Progressive lytic destruction of oligodendrocytes produces expanding foci of demyelination.
Key Virologic Concepts
- Archetype JCPyV: The non-pathogenic form found in urine; has a stable NCCR that does not efficiently infect glial cells
- Prototype (rearranged) JCPyV: Contains deletions, duplications, and rearrangements in the NCCR; acquires enhanced promoter activity in oligodendrocytes and astrocytes
- Cellular tropism: Oligodendrocytes (primary target → demyelination), astrocytes (bizarre enlarged forms seen histologically), and possibly cerebellar granule cell neurons (in JCV granule cell neuronopathy)
- Immune evasion: JCPyV does not encode immune evasion genes; PML is fundamentally a disease of immune failure, not viral virulence
- Viral receptor: JCPyV binds to serotonin receptor 5-HT2A on glial cells — basis for early (unsuccessful) trials of mirtazapine
Risk Settings and Epidemiology
Understanding the specific immunosuppressive context in which PML develops is critical, as the risk profile, clinical course, and management differ substantially by etiology.
| Risk Setting | Mechanism of Immune Impairment | Estimated PML Incidence | Key Considerations |
|---|---|---|---|
| HIV/AIDS | CD4+ T-cell depletion (<200 cells/μL) | 1–5% of AIDS patients (pre-ART era) | Most common historical cause; incidence decreased 50–60% with ART; may be AIDS-presenting illness |
| Natalizumab (MS) | Blocks α4-integrin, preventing lymphocyte CNS trafficking | ~4/1,000 in high-risk patients | Risk stratified by JCV Ab index, prior IS use, duration; risk peaks >24 months |
| Rituximab / anti-CD20 | B-cell depletion; indirect T-cell effects | ~1/25,000 (RA); higher in lymphoma | Often in context of prior or concurrent immunosuppression; delayed recognition common |
| Hematologic malignancies | Disease-related immune dysfunction + chemotherapy | Variable; CLL, lymphoma highest risk | May occur with fludarabine, bendamustine, other agents |
| Organ transplant | Chronic pharmacologic immunosuppression | ~1/1,000 to 1/10,000 | Kidney > heart > liver; tacrolimus, mycophenolate implicated |
| Other immunosuppressants | Variable mechanisms | Rare individual reports | Fingolimod, dimethyl fumarate (rare, with lymphopenia), methotrexate, azathioprine |
| Minimal/no immunosuppression | Occult immune dysfunction, idiopathic | Extremely rare | Should prompt evaluation for occult malignancy or immune deficiency |
Natalizumab-Associated PML Risk Stratification
Natalizumab-associated PML represents the most well-characterized iatrogenic risk setting and has driven development of a detailed risk stratification algorithm that is essential knowledge for MS neurologists.
Three-Factor Risk Model for Natalizumab-PML
- Factor 1 — JCV antibody status: JCV Ab-negative patients have a very low risk (~0.1/1,000 or less); seroconversion occurs at ~2–3% per year, necessitating retesting every 6 months
- Factor 2 — JCV antibody index: Among JCV Ab-positive patients, an index ≤0.9 confers lower risk; index >1.5 confers substantially higher risk; the index reflects viral antibody titer and correlates with reactivation probability
- Factor 3 — Prior immunosuppressant use: History of chemotherapy, mitoxantrone, azathioprine, methotrexate, or mycophenolate increases risk approximately 3-fold
- Duration of therapy: Risk increases markedly after 24 months of treatment; risk is low in the first 12 months regardless of other factors
| JCV Ab Status | Ab Index | Prior IS Use | Duration ≤24 mo | Duration >24 mo |
|---|---|---|---|---|
| Negative | N/A | Any | ~0.1/1,000 | ~0.1/1,000 |
| Positive | ≤0.9 | No | ~0.1/1,000 | ~0.3/1,000 |
| Positive | ≤0.9 | Yes | ~0.2/1,000 | ~0.7/1,000 |
| Positive | >1.5 | No | ~0.2/1,000 | ~4/1,000 |
| Positive | >1.5 | Yes | ~0.4/1,000 | ~11/1,000 |
Clinical Presentation
PML presents with subacute, progressive focal neurologic deficits that reflect the location of white matter lesions. The absence of systemic signs of infection is a hallmark feature.
Characteristic Features
Classic PML Presentation
- Motor deficits: Hemiparesis or monoparesis is the most common presenting symptom (~50%), reflecting corticospinal tract involvement in hemispheric white matter
- Visual field deficits: Homonymous hemianopia or cortical blindness from parieto-occipital involvement; may be the presenting complaint in 25–30% of cases
- Cognitive/behavioral changes: Personality changes, executive dysfunction, confusion, progressing to dementia; especially frontal lobe involvement
- Cerebellar ataxia: Gait and limb ataxia; involvement of cerebellar peduncles; more common in natalizumab-PML
- Language deficits: Aphasia when dominant hemisphere white matter affected
- Seizures: Occur in ~20% of patients, more common in natalizumab-PML than HIV-PML
Red Flags That Distinguish PML from MS Relapse
- Progression: PML deficits progress steadily over weeks to months; MS relapses typically reach nadir within days and then stabilize or improve
- Absence of inflammation: No fever, no meningismus, no headache, normal inflammatory markers — in contrast to CNS infections or tumefactive MS
- Cortical/subcortical pattern: PML lesions extend to and involve the subcortical U-fibers (juxtacortical) — MS plaques are typically periventricular, ovoid, and follow venous drainage
- Continuous expansion: PML lesions enlarge contiguously rather than appearing as scattered new lesions in different locations
- No enhancement: PML lesions do not enhance on gadolinium MRI (unless IRIS has developed)
Variants of PML
| Variant | Clinical Features | Key Distinctions |
|---|---|---|
| Classic PML | Multifocal white matter disease, progressive deficits | Most common form; described above |
| PML-IRIS | Inflammatory variant with contrast enhancement, edema | Occurs with immune reconstitution; may unmask or worsen PML |
| JCV granule cell neuronopathy | Isolated cerebellar syndrome; progressive ataxia | Selective infection of cerebellar granule cells; cerebellar atrophy on MRI; CSF JCV PCR may be negative |
| JCV encephalopathy | Cortical gray matter involvement; cognitive decline, seizures | Cortical neuron infection; cortical signal changes without classic white matter involvement |
| JCV meningitis | Aseptic meningitis, often self-limited | Rare; CSF JCV PCR positive without parenchymal disease |
Neuroimaging
MRI is the most important diagnostic tool for PML and often provides the first clue before CSF confirmation is available. Recognition of the characteristic imaging pattern is critical.
MRI Features of PML
Classic MRI Findings
- T2/FLAIR hyperintensity: Asymmetric, multifocal, confluent white matter lesions; characteristically involve the subcortical U-fibers (a key distinguishing feature from MS)
- Topographic predilection: Parieto-occipital white matter is most commonly affected, followed by frontal lobes; posterior fossa involvement (cerebellar peduncles, pons) occurs in 10–15%
- T1 hypointensity: Lesions are hypointense on T1 sequences, reflecting tissue destruction (as opposed to edema alone)
- No mass effect: Despite sometimes large lesion volumes, there is characteristically no significant mass effect or midline shift — reflecting demyelination rather than space-occupying pathology
- No contrast enhancement: In classic PML, lesions do not enhance with gadolinium; the presence of enhancement should raise concern for IRIS or an alternative diagnosis
- DWI/ADC changes: The advancing edge of PML lesions shows restricted diffusion on DWI (bright on DWI, dark on ADC) representing active viral-mediated demyelination; the central, established portion shows facilitated diffusion
- Sparing of cortical gray matter: In classic PML, the cortex is spared even as the underlying white matter is destroyed up to the cortical ribbon; this creates the "scalloped" subcortical pattern
| MRI Feature | PML | MS | CNS Lymphoma |
|---|---|---|---|
| U-fiber involvement | Characteristic | Uncommon (juxtacortical but not U-fiber) | Variable |
| Enhancement | Absent (unless IRIS) | Open ring or solid enhancement | Homogeneous (immunocompetent) or ring (HIV) |
| Mass effect | Absent | Minimal | Present |
| Distribution | Asymmetric, subcortical | Periventricular, ovoid, Dawson fingers | Periventricular, may cross corpus callosum |
| T1 signal | Hypointense (destructive) | Variable; black holes chronic | Iso- to hypointense |
| DWI restricted diffusion | At leading edge | In acute plaques | Diffusely restricted |
Monitoring MRI in At-Risk Patients
For MS patients on natalizumab, surveillance MRI every 3–6 months is recommended for early detection of subclinical PML. Higher-risk patients (JCV Ab index >1.5, treatment >24 months) should undergo MRI every 3–4 months. Early PML lesions may be subtle — small, punctate white matter changes that can be mistaken for new MS activity. Comparison with prior scans and attention to subcortical U-fiber involvement are essential.
Diagnosis
The diagnosis of PML rests on the combination of a compatible clinical presentation, characteristic MRI findings, and laboratory confirmation of JCPyV in the CNS.
Diagnostic Algorithm
| Diagnostic Level | Criteria | Certainty |
|---|---|---|
| Definite PML | Compatible clinical + MRI findings + histopathologic confirmation (brain biopsy with JCV immunohistochemistry or in situ hybridization) | Gold standard |
| Probable PML | Compatible clinical + MRI findings + positive CSF JCV PCR | Sufficient for clinical management in most cases |
| Possible PML | Compatible clinical + MRI findings + negative CSF JCV PCR | Cannot exclude PML; repeat LP or biopsy may be needed |
CSF Analysis
CSF JCV PCR and Other Findings
- JCV PCR sensitivity: ~75–80% overall; sensitivity is lower in natalizumab-PML (~60%) than HIV-PML (~80–90%) due to lower viral loads; ultrasensitive PCR assays with detection limits <10 copies/mL improve yield
- JCV PCR specificity: ~95–99%; false positives are rare but can occur with very low copy numbers
- Quantitative PCR: Viral load in CSF correlates loosely with disease burden and prognosis; very high loads (>105 copies/mL) portend worse outcome
- Repeat testing: If initial CSF JCV PCR is negative but clinical suspicion remains high, repeat LP in 2–4 weeks; viral load may increase as disease progresses
- Other CSF findings: Typically bland — mild pleocytosis (<20 cells/μL), mildly elevated protein, normal glucose; significant pleocytosis suggests IRIS or alternative diagnosis
- CSF JCV-specific antibodies: Under investigation as supplementary diagnostic marker
Brain Biopsy
Brain biopsy is reserved for cases with high clinical suspicion but negative CSF JCV PCR. The classic histopathologic triad includes: (1) multifocal demyelination, (2) bizarre enlarged astrocytes with hyperchromatic nuclei, and (3) oligodendrocytes with enlarged, glassy intranuclear inclusions ("ground glass" nuclei). JCV can be confirmed by immunohistochemistry or in situ hybridization. Stereotactic biopsy targeting the advancing edge of a lesion improves diagnostic yield.
Treatment
There is no approved antiviral therapy for JCPyV. The cornerstone of management is restoration of immune function to enable endogenous viral control.
Management by Etiology
| Setting | Primary Intervention | Additional Measures | Notes |
|---|---|---|---|
| HIV/AIDS | Initiate or optimize ART immediately | Monitor for IRIS; supportive care | Immune reconstitution is the only proven strategy to improve survival |
| Natalizumab-MS | Discontinue natalizumab; plasma exchange (PLEX) or immunoadsorption ×5 sessions | PLEX accelerates natalizumab clearance (half-life reduced from ~16 days to ~3 days); maraviroc considered for IRIS prevention (limited evidence) | Goal: restore lymphocyte trafficking to CNS; be prepared for IRIS within 1–5 weeks of PLEX |
| Rituximab / anti-CD20 | Discontinue rituximab | No reversal agent; half-life ~20 days; immune reconstitution slow (months) | B-cell recovery may take 6–12 months; supportive care critical |
| Organ transplant | Reduce immunosuppression judiciously | Balance PML treatment against graft rejection risk | Collaborative decision with transplant team; often switch to lower-risk regimen |
| Hematologic malignancy | Modify chemotherapy regimen | Immune reconstitution limited by underlying disease | Worst prognosis among all PML settings; mortality >50% |
Investigational Therapies
Emerging and Experimental Approaches
- Checkpoint inhibitors (pembrolizumab): PD-1 blockade to reinvigorate exhausted JCV-specific T cells; case reports and small series show benefit in some patients; risk of immune-related adverse events and graft rejection in transplant patients
- Cidofovir / brincidofovir: In vitro anti-JCPyV activity; clinical trials have not demonstrated consistent benefit; largely abandoned
- Mirtazapine: Blocks 5-HT2A receptor (JCPyV entry receptor); theoretical rationale but no proven clinical efficacy; sometimes used empirically given favorable safety profile
- Mefloquine: Anti-JCPyV activity in vitro; randomized trial in HIV-PML showed no benefit
- Interleukin-7: Under investigation to boost T-cell responses; limited data
- JCV-specific adoptive T-cell therapy: Experimental; donor-derived or expanded JCV-specific cytotoxic T lymphocytes; promising early results
PML-IRIS (Immune Reconstitution Inflammatory Syndrome)
PML-IRIS occurs when reconstitution of the immune system triggers a vigorous inflammatory response against JCPyV-infected tissue. This paradoxical worsening can be more acutely dangerous than PML itself and is a major management challenge.
Pathophysiology and Timing
IRIS develops when immune cells, previously unable to access or respond to JCPyV in the CNS, become activated and mount an inflammatory attack. In HIV-PML, IRIS typically occurs 1–12 weeks after ART initiation. In natalizumab-PML, IRIS develops 1–5 weeks after PLEX or drug washout. IRIS can unmask previously subclinical PML (unmasking IRIS) or worsen established PML (paradoxical IRIS).
Clinical Features of PML-IRIS
- Paradoxical clinical worsening: New or worsening focal neurologic deficits, increased edema, new mass effect, altered consciousness — occurring after immune reconstitution rather than before
- MRI changes: New contrast enhancement (key distinguishing feature), increased edema and mass effect, lesion expansion; may develop midline shift
- Can be fatal: Severe IRIS with brainstem involvement, massive edema, or herniation can be rapidly lethal; mortality ~15–30%
- Differentiation from PML progression: Enhancement and edema point to IRIS; continued T2 expansion without enhancement suggests ongoing PML without immune response
- Paradox: Some degree of IRIS is actually beneficial (indicates immune response against JCV); the challenge is when inflammation becomes destructively excessive
Management of PML-IRIS
IRIS Treatment Approach
- Corticosteroids: IV methylprednisolone 1 g/day for 3–5 days followed by oral taper is the mainstay for severe IRIS with mass effect or clinical deterioration; must balance against further immunosuppression
- Continue ART in HIV: ART should NOT be discontinued during IRIS (stopping would remove the beneficial immune reconstitution)
- Monitoring: Frequent MRI (every 1–2 weeks during IRIS); close clinical assessment for signs of herniation
- Osmotic therapy: Mannitol or hypertonic saline for acute elevated ICP from IRIS-related edema
- Maraviroc: CCR5 antagonist; proposed to reduce inflammatory cell trafficking; some use in natalizumab-PML-IRIS prophylaxis but evidence is limited
Prognosis and Long-Term Outcomes
| Setting | Mortality | Factors Favoring Survival | Functional Outcomes in Survivors |
|---|---|---|---|
| HIV-PML (pre-ART) | ~90% within 1 year | N/A | Rare survival, severe disability |
| HIV-PML (ART era) | 30–50% | Early ART, CD4 recovery >100, low CSF JCV viral load, limited MRI disease burden | Variable; many survivors have moderate-to-severe disability |
| Natalizumab-PML | ~23–25% | Early detection (MRI surveillance), younger age, lower JCV viral load, limited lesion volume at diagnosis | ~40% achieve functional independence (mRS ≤2); ~35% moderate disability |
| Hematologic malignancy | >50–60% | Ability to reduce immunosuppression; immune recovery | Poor; limited by underlying disease |
| Transplant-associated | ~40–50% | Ability to reduce immunosuppression without graft loss | Variable |
Monitoring and Prevention
Surveillance in MS Patients on Natalizumab
Recommended Monitoring Protocol
- JCV antibody testing: Before initiation and every 6 months during treatment; seroconversion from negative to positive changes risk profile
- JCV antibody index: Quantitative index aids further risk stratification in seropositive patients; index >1.5 associated with higher risk
- MRI surveillance: Every 3–6 months depending on risk profile; higher-risk patients (JCV Ab+, index >1.5, >24 months treatment) should have MRI every 3–4 months
- Clinical vigilance: Educate patients and caregivers about symptoms of PML; any new neurologic symptom should prompt urgent MRI
- Extended interval dosing (EID): Natalizumab infusions every 6–8 weeks (instead of standard 4 weeks) may reduce PML risk while maintaining efficacy; TOUCH registry and observational data suggest ≥50% risk reduction; increasingly adopted in practice
Considerations When Switching from Natalizumab
Discontinuation of natalizumab carries risk of severe MS rebound activity. The optimal strategy for transitioning to an alternative DMT while minimizing both MS rebound and residual PML risk remains debated. A washout period of 8–12 weeks is typical before initiating fingolimod, ocrelizumab, or other therapies. During the washout, MS disease activity monitoring with MRI and clinical assessment is essential. Bridge therapy with corticosteroids may be considered.
Special Considerations
PML in Other Neurologic Therapies
PML Risk with Non-Natalizumab MS Therapies
- Fingolimod: Rare PML cases reported, almost exclusively in the setting of prolonged lymphopenia (lymphocyte count <200/μL); monitoring lymphocyte counts is essential; discontinue if count <200 for >6 months
- Dimethyl fumarate: Rare PML cases, associated with severe prolonged lymphopenia (absolute lymphocyte count <500 for >6 months); monitoring ALC every 6 months is standard
- Ocrelizumab / anti-CD20: Rare PML cases in MS, though more reported in rheumatologic and oncologic settings; carry-over PML from natalizumab switch must be distinguished from de novo ocrelizumab-PML
- Key principle: PML risk with these agents is orders of magnitude lower than natalizumab; vigilance is appropriate but should not preclude their use when indicated
Infection Control
JCPyV is not transmitted person-to-person in clinical settings, and standard precautions are adequate. No isolation is required for hospitalized patients with PML. Primary infection occurs in childhood through presumed respiratory or urinary-oral routes.
References
- Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438.
- Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37-51.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
- Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925-933.
- Clifford DB, De Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438-446.
- Miskin DP, Herman ST, Engel CE, et al. JC polyomavirus granule cell neuronopathy: diagnostic challenges and treatment outcomes. Neurology. 2016;87(13):1350-1356.
- Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425-437.
- Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis. 2009;48(10):1459-1466.
- Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255-273.
- Martinot M, Ahle G, Petrosyan I, et al. Progressive multifocal leukoencephalopathy after treatment with nivolumab. Emerg Infect Dis. 2018;24(8):1594-1596.
- Kartau M, Sipila JO, Auvinen E, et al. Progressive multifocal leukoencephalopathy: current insights. Degener Neurol Neuromuscul Dis. 2019;9:109-121.
- Balduzzi A, Lucchini G, Bentivegna W, et al. Progressive multifocal leukoencephalopathy treated with interleukin-2, pembrolizumab, and adoptive T-cell therapy. Blood Adv. 2021;5(1):41-44.
- Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010;68(3):384-391.
- Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885-889.